NEW YORK, October 12, 2022 (GLOBE NEWSWIRE) – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action lawsuit against Co-Diagnostics, Inc. (“Co-Dx” or the “Company”) (NASDAQ: CODX) in the United States District Court for the Southern District of New York; Dwight H. Egan, the Company’s Chief Executive Officer, President and CEO; and Brian L. Brown, the Company’s Chief Financial Officer and Secretary (“Defendants”).

The lawsuit alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the SEC and is being asserted by the plaintiff on behalf of all persons and Entities that purchased the publicly traded securities of Co-Dx during the period from May 12, 2022 through the market close on August 11, 2022 (4:00 p.m. ET), inclusive (the “Class Period”).

If you are a member of the proposed class action, you have no later than October 17, 2022, to request the court to serve as lead plaintiff in the proposed class action. You do not have to aspire to become Lead Plaintiff to participate in a possible recovery.

If you have suffered significant losses and would like to appear as lead plaintiff, please email attorneys Jason A. Uris ([email protected]) or Donald R Hall ([email protected]), or contact them by phone at 212-687-1980.